References
1. Sethi, S., New ’Antigens’ in Membranous Nephropathy. J Am Soc Nephrol, 2021. 32 (2): p. 268-278.
2. JONES, D., Nephrotic glomerulonephritis. The American journal of pathology, 1957. 33 (2): p. 313-29.
3. Beck, L.H., Jr., et al., M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009. 361 (1): p. 11-21.
4. Tomas, N.M., et al., Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med, 2014.371 (24): p. 2277-2287.
5. Ronco, P. and H. Debiec, Membranous nephropathy: current understanding of various causes in light of new target antigens. Curr Opin Nephrol Hypertens, 2021.
6. Schieppati, A., et al., Nonimmunosuppressive therapy of membranous nephropathy. Seminars in Nephrology, 2003. 23 (4): p. 333-339.
7. Gansevoort, R.T., et al., Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol Dial Transplant, 1992. 7 Suppl 1 : p. 91-6.
8. Kosmadakis, G., et al., Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. Scand J Urol Nephrol, 2010.44 (4): p. 251-6.
9. Mizuno, T., et al., KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury. Oncology, 2012. 82 (6): p. 354-9.
10. Tran, T.H., et al., Overview of current and alternative therapies for idiopathic membranous nephropathy. Pharmacotherapy, 2015.35 (4): p. 396-411.
11. De Vriese, A.S., et al., A Proposal for a Serology-Based Approach to Membranous Nephropathy. Journal of the American Society of Nephrology, 2017. 28 (2): p. 421-430.
12. Cattran, D.C. and P.E. Brenchley, Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int, 2017. 91 (3): p. 566-574.
13. Vacchi, C., et al., Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context, 2021. 10 .
14. Semac, I., et al., Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res, 2003. 63 (2): p. 534-40.
15. Bonavida, B., Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 2007. 26 (25): p. 3629-36.
16. Manches, O., et al., In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood, 2003.101 (3): p. 949-54.
17. Wang, S.Y., et al., NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood, 2008.111 (3): p. 1456-63.
18. Roccatello, D., et al., New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.Autoimmun Rev, 2016. 15 (6): p. 529-38.
19. Ponticelli, C., et al., A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int, 1995. 48 (5): p. 1600-4.
20. Ruggenenti, P., et al., Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol, 2012. 23 (8): p. 1416-25.
21. Cravedi, P., et al., Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol, 2011. 33 (5): p. 461-8.
22. Roccatello, D., R. Fenoglio, and S. Sciascia, Efficacy of low or standard dose rituximab as compared to Ponticelli’s regimen in membranous nephropathy. Nephrology Dialysis Transplantation, 2019.34 : p. a123.
23. Ruggenenti, P., F.C. Fervenza, and G. Remuzzi, Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol, 2017. 13 (9): p. 563-579.
24. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int, 2020. 98 (4s): p. S1-s115.
25. Dahan, K., et al., Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol, 2017. 28 (1): p. 348-358.
26. Seitz-Polski, B., et al., Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. J Am Soc Nephrol, 2018. 29 (2): p. 401-408.
27. Rosenzwajg, M., et al., B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int, 2017. 92 (1): p. 227-237.
28. van den Brand, J., et al., Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J Am Soc Nephrol, 2017. 28 (9): p. 2729-2737.
29. Fervenza, F.C., et al., Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med, 2019.381 (1): p. 36-46.
30. Fenoglio, R., et al., Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli’s regimen in membranous nephropathy. J Nephrol, 2020.
31. Cravedi, P., et al., Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 2007. 2 (5): p. 932-937.
32. Sugiura, H., et al., Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract, 2011. 117 (2): p. c98-105.
33. Ramachandran, R., et al., CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy. Kidney Int Rep, 2017.2 (1): p. 89-90.
34. Moroni, G., et al., Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant, 2017. 32 (10): p. 1691-1696.
35. Remuzzi, G., et al., Rituximab for idiopathic membranous nephropathy. Lancet, 2002. 360 (9337): p. 923-4.
36. Ruggenenti, P., et al., Rituximab for idiopathic membranous nephropathy (IMN): Renal biopsy findings predict response to treatment.Journal of the American Society of Nephrology, 2003. 14 : p. 528A-528A.
37. Ruggenenti, P., et al., Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol, 2006.1 (4): p. 738-48.
38. Fervenza, F.C., et al., Response to ’rituximab in membranous nephropathy’. Kidney International, 2008. 74 (3): p. 392-392.
39. Fervenza, F.C., et al., Rituximab treatment of idiopathic membranous nephropathy. Kidney International, 2008. 73 (1): p. 117-125.
40. Fervenza, F.C., et al., Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study. Clinical Journal of the American Society of Nephrology, 2010. 5 (12): p. 2188-2198.
41. Busch, M., et al., Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Clin Nephrol, 2013.80 (2): p. 105-13.
42. Bagchi, S., et al., Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience. Clin Kidney J, 2018. 11 (3): p. 337-341.
43. Huang, L., et al., Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis. Int Urol Nephrol, 2020.
44. Zhang, J., et al., Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis. Eur Rev Med Pharmacol Sci, 2018. 22 (22): p. 8021-8029.
45. Lu, W., et al., Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. Medicine (Baltimore), 2020. 99 (16): p. e19804.
46. Dahan, K., et al., Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the American Society of Nephrology, 2017. 28 (1): p. 348-358.
47. Fervenza, F.C., et al., A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron, 2015. 130 (3): p. 159-68.
48. Ruggenenti, P., P. Cravedi, and G. Remuzzi, Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol, 2009. 5 (2): p. 76-7.
49. Remuzzi, G., et al., Rituximab for idiopathic membranous nephropathy. Lancet, 2002. 360 (9337): p. 923-924.
50. Seitz-Polski, B., et al., High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc Nephrol, 2019. 14 (8): p. 1173-1182.
Table 1 Characteristics of the studies on the comparison of RTX and traditional therapies for remission included in the analysis.